Jupiter Neurosciences, Inc
Jupiter Neurosciences, Inc. is a clinical-stage research and development company built around JOTROL, an enhanced oral resveratrol formulation designed to address neuro-inflammation. The company is advancing JOTROL for rare diseases and larger neurology indications, while also exploring a consumer health and longevity line through a separate direct-to-consumer initiative.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaJOTROL and related drug-development programs targeting neuro-inflammation and neurological disease.
Potential therapeutic uses of JOTROL in orphan and ultra-rare disorders such as MPS I and Friedreich’s ataxia.
Planned direct-to-consumer nutritional products focused on beauty-from-within, aging and healthspan.
Outsourced business development, CMC, regulatory and clinical trial management support in Asia.
Asiakkaat
The company’s primary customers are not yet commercial end-users; it is still in the clinical development phase and has generated no product sales. Its near-term counterparties are research partners, service providers, potential licensees, and clinical/regulatory collaborators, while future customers would include patients, physicians, and possibly consumers for the longevity line.
Future users of JOTROL in Parkinson’s disease and MCI/early Alzheimer’s if clinical data support approval.
Patients and specialists in orphan indications such as MPS I, Friedreich’s ataxia and MELAS.
Pharma or regional partners that may license JOTROL rights, especially in Southeast Asia.
Direct-to-consumer purchasers of planned nutritional longevity products launched through a subsidiary.
CMC, regulatory affairs and clinical trial management firms supporting development execution.
Strategia
The company’s strategy is to advance JOTROL through clinical development while using partnerships to extend reach and reduce cash burn. It is prioritizing biomarker-driven Parkinson’s work, selective progress on Alzheimer’s-related programs, and regional business development in Asia to improve the odds of an out-licensing transaction. In parallel, it is testing a consumer health extension through a separate subsidiary and direct-to-consumer model.
Clinical data are needed to support partnering, licensing and eventual commercialization.
Regional partners can lower execution cost and accelerate out-licensing opportunities.
A DTC line could create a non-pharma revenue stream and broaden the brand.
Maantiede
Jupiter Neurosciences is headquartered in the United States and is building its initial commercial and capital markets base there, including Nasdaq listing activity. Operationally, it is expanding business development in Asia, with a particular focus on Hong Kong and Southeast Asian territories as a route to out-licensing and development support. The planned consumer product line is also aimed at the U.S. market, while international commercialization is expected to rely on regional partners.
Riskit
The company remains pre-revenue and dependent on external financing, so clinical setbacks or capital-market weakness could force delays or program cuts. Its business also depends on proving JOTROL’s differentiation, protecting intellectual property, and managing supply-chain and regulatory execution across multiple development paths. The planned consumer products add competitive and execution risk in a crowded nutraceutical market.
- Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has recurring losses, negative operating cash flow and depends on private equity and financings.
Kohdistuu: Corporate liquidity and program continuity
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
JOTROL’s value depends on positive biomarker and trial results in Parkinson’s and related indications.
Kohdistuu: Lead asset valuation and partnering prospects
- Intellectual property disputesVaikutus: KorkeaTodennäköisyys: Matala
Patent challenges or competing bioavailability technologies could erode differentiation.
Kohdistuu: Platform protection and licensing power
- Supply-chain and manufacturing executionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company relies on third-party partners for CMC and product development support.
Kohdistuu: Launch timing and product quality
- Consumer market competitionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Longevity and nutraceutical products face established brands and crowded shelves.
Kohdistuu: New DTC revenue opportunity
Kirjanpito
Harkinnanvaraiset erätRecurring losses and negative cash flow require management to evaluate whether operations can continue.
Vaikutus: May influence auditor emphasis and investor perception of solvency
The company issued shares and options for services, requiring fair value measurement and expense recognition.
Vaikutus: Affects G&A expense, equity balances and dilution
CEO loans and amounts due to a CFO-owned entity must be tracked and disclosed carefully.
Vaikutus: Affects liabilities, interest expense and related-party transparency
Clinical supplies, trial management and development services flow through R&D and drive period losses.
Vaikutus: Affects operating loss and comparability across quarters
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
ProMIS Neurosciences Inc.
PMN · Pharmaceutical Preparations
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
NeuroSense Therapeutics Ltd.
NRSNW · Pharmaceutical Preparations
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Firefly Neuroscience, Inc
AIFF · Services-Prepackaged Software
Päivitetty: 24.9.2026